Editas Medicine, Inc.
Moat Score — Editas Medicine, Inc.
Total Moat Score
7 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Editas holds 153 U.S. and 68 European patents (in-licensed from Broad Institute/Harvard plus owned IP) covering both Cas9 and Cas12a gene-editing enzymes — a dual-enzyme platform breadth that is genuinely rare and has already proven monetizable through third-party licensing. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | As a clinical-stage biotech with no commercial manufacturing at scale, Editas has no cost advantage; CRISPR therapeutic manufacturing remains complex and expensive industry-wide. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With no approved products, any future pricing power for EDIT-401 or other candidates is entirely speculative, though large-market indications like hyperlipidemia could eventually support substantial commercial pricing if the therapy reaches approval. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Gene-editing therapeutics carry no network effect; value is determined by clinical efficacy and regulatory approval, not user or platform dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | No commercial product exists yet, so there are no patients or prescribers to switch. A one-time in vivo gene-editing therapy, if approved, could carry unusually high 'switching costs' in the sense of being curative and non-repeatable, but this is entirely prospective. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 1 / 5 | Editas's lead indication, hyperlipidemia, is a large, non-niche market, which cuts against a classic efficient-scale moat; its deprioritized hemoglobinopathy programs target narrower populations but are not the current strategic focus. |